Joint study on human genomic analysis of drug resistance
人类耐药性基因组分析联合研究
基本信息
- 批准号:03044118
- 负责人:
- 金额:$ 5.12万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for international Scientific Research
- 财政年份:1991
- 资助国家:日本
- 起止时间:1991 至 1993
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The mechanisms of gene amplification and expression of human multidrug resistance 1(MDR1) gene have been studied during acquisition of drug resistance by using genomic DNA cloned into phase or yeast artificial chromosome(YAC)vector.1. The promoter region of MDR1 gene was isolated from phage library to clarify the structure of transcriptional regulatory domain. Regulatory elements which respond to anticancer agents and to UV have been identified by deletion analysis. We propose that MDR1 gene is a member of the stress inducible genes and the inducibility is the underlying mechanism by which cells acquire drug resistance after chemotherapy.2.We tried to construct a map of this region to determine the long range genomic organization of MDR region and to isolate diagnostic probe for drug resistance. Twenty YAC clones around MDR1 gene region were isolated from the total human and the chromosome 7 specific library which was constructed at Washington University. 1.5Mb contigu has been built f … More rom these clones by STS content mapping procedure. Physical map spanning 600kb including MDR1 gene was also constructed using rare cutter enzymes.3.The YAC clone human containing MDR1 gene was transferred to mouse cell line by polyethylene glycol mediated spheroplast fusion method. Pulsed-field gel electrophoresis and PCR analysis of the fusion line showed intact structure of the YAC clone transferred. The step-wise gene amplification and expression of human MDR1 gene were observed during acquisition of step-wise resistance to vincristine, indicating functional intactness of the clone. In contrast, amplification and expression of endogenous mouse MDRI gene were not observed, suggesting an unknown mechanism which permit, selective expression of human MDR1 gene.4.The mechanisms of drug resistance to topoisomerase targeting agents were also investigated. Decrease of level of topoisomerase II was observed in etoposide resistant cells. We also found that the topoisomerase II gene is heat inducible. The promoter region of the human topoisomerase II was isolated for further study of topoisomerase II gene expression. Less
利用克隆入相的基因组DNA或酵母人工染色体(YAC)载体,研究了人多药耐药1(MDR1)基因在获得耐药过程中的基因扩增和表达机制。从噬菌体文库中分离mdr1基因启动子区域,以明确其转录调控结构域的结构。通过缺失分析已经确定了对抗癌药物和紫外线有反应的调控元件。我们认为mdr1基因是应激诱导基因中的一员,诱导性是细胞在化疗后获得耐药的潜在机制。2.我们试图构建该区域的图谱,以确定mdr区的远程基因组组织,并分离出耐药的诊断探针。从全人类和华盛顿大学构建的7号染色体特异性文库中分离到mdr1基因周围的20个YAC克隆。为…构建了1.5Mb的Contigu通过STS内容映射程序从这些克隆中获得更多信息。利用稀有切割酶构建了包含mdr1基因的600kb物理图谱。3.用聚乙二醇介导球形体融合的方法将含有mdr1基因的YAC克隆人转入小鼠细胞系。融合株的脉冲场凝胶电泳法和聚合酶链式反应分析表明,导入的YAC克隆结构完整。在获得对长春新碱的阶段性耐药过程中,观察到人MDR1基因的阶段性扩增和表达,表明克隆的功能是完整的。相反,没有观察到内源性小鼠mdr1基因的扩增和表达,这可能是一种未知的机制,允许选择性表达人mdr1基因。4.还研究了拓扑异构酶靶向药物耐药的机制。在依托泊苷耐药细胞中,拓扑异构酶II水平降低。我们还发现拓扑异构酶II基因是热诱导的。分离了人拓扑异构酶II的启动子区域,为进一步研究拓扑异构酶II基因的表达奠定了基础。较少
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Takeshi Uchiumi: "Activation of the pronoter of the human multidrug resistance(MDR1)gene in response to ultraviolet light irradiation." Cell Growth & Differ.4. (1993)
Takeshi Uchiumi:“人类多药耐药性(MDR1)基因的启动子响应紫外线照射而被激活。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
K.Kohno: "The Mechanism and New Approach on Drug-resistance of Cancer Cells." Elesevier, 7 (1993)
K.Kohno:“癌细胞耐药的机制和新方法”。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
K.Matsuo: "Enhanced expression of DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells." Cancer Res.53. 1085-1090 (1993)
K.Matsuo:“人类表皮样癌 KB 细胞中 DNA 拓扑异构酶 II 基因的表达增强,以响应热休克应激。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
M.Nakagawa: "Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line." J.Urology. 150. 1970-1973 (1993)
M.Nakakawa:“减少人前列腺癌 PC-3 细胞系顺铂耐药变体中的药物积累。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
M.Wada: "Chimeric YACs were generated at unreduced rates in conditions that suppress coligation." Nucleic Acid.Res.(in press). (1994)
M.Wada:“在抑制交联的条件下,嵌合 YAC 的生成率并未降低。”
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KUWANO Michihiko其他文献
KUWANO Michihiko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KUWANO Michihiko', 18)}}的其他基金
Novel approach to overcome malignant cancer by targeting Y-box binding protein-1(YB-1)
通过靶向Y-box结合蛋白-1(YB-1)克服恶性肿瘤的新方法
- 批准号:
24650646 - 财政年份:2012
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Human Y-box binding protein1(YB-1) : Mechanism for the nuclear translocation and its role of tumor growth and drug resistance-
人Y-box结合蛋白1(YB-1):核转位机制及其在肿瘤生长和耐药性中的作用-
- 批准号:
19590324 - 财政年份:2007
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ABC Transporters in Cancer and Other Diseases
癌症和其他疾病中的 ABC 转运蛋白
- 批准号:
11694286 - 财政年份:1999
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Joint Study on Angiogenesis and Growth Factor Responses
血管生成和生长因子反应的联合研究
- 批准号:
06044179 - 财政年份:1994
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for international Scientific Research
Human model system for angiogenesis and molecular mechanisms on function of growth factors involving in the angiogenesis
人体血管生成模型系统及生长因子参与血管生成功能的分子机制
- 批准号:
04454175 - 财政年份:1992
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
Oligosaccharide Analysis of the Low Density Lipoprotein Receptors in Golgi Mutants
高尔基体突变体低密度脂蛋白受体的寡糖分析
- 批准号:
63044114 - 财政年份:1989
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for international Scientific Research
Classification of human hypercholesterolemia by using somatic cell mutants with altered response to low density lipoprotein.
通过使用对低密度脂蛋白反应改变的体细胞突变体对人类高胆固醇血症进行分类。
- 批准号:
62870012 - 财政年份:1987
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for Developmental Scientific Research
Altered structure of LDL receptor and cholesterol metabolic defects.
LDL 受体结构改变和胆固醇代谢缺陷。
- 批准号:
62480134 - 财政年份:1987
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
Somatic Cell Genetic Mutants with Altered Cholesterol Metabolism and Altered Endocytosis of Low Density Lipoprotein
胆固醇代谢改变和低密度脂蛋白内吞作用改变的体细胞遗传突变体
- 批准号:
60480142 - 财政年份:1985
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
相似海外基金
Overcoming multi drug resistance in 3D breast cancer cell model by pH-sensitive biomimetic nanoparticles
pH敏感仿生纳米颗粒克服3D乳腺癌细胞模型中的多重耐药性
- 批准号:
20K20203 - 财政年份:2020
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10439626 - 财政年份:2020
- 资助金额:
$ 5.12万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10626002 - 财政年份:2020
- 资助金额:
$ 5.12万 - 项目类别:
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10029257 - 财政年份:2020
- 资助金额:
$ 5.12万 - 项目类别:
Investigating multi-drug resistance in lung cancer using metabolomics and cell biology
利用代谢组学和细胞生物学研究肺癌的多药耐药性
- 批准号:
2368566 - 财政年份:2020
- 资助金额:
$ 5.12万 - 项目类别:
Studentship
New Multi-Drug Resistance Mechanism in Multiple Myeloma
多发性骨髓瘤多重耐药新机制
- 批准号:
10187534 - 财政年份:2020
- 资助金额:
$ 5.12万 - 项目类别:
Predicting evolutionary dynamics of multi-drug resistance
预测多重耐药性的进化动态
- 批准号:
MR/R024936/1 - 财政年份:2017
- 资助金额:
$ 5.12万 - 项目类别:
Fellowship
Strategies overcome Multi-drug resistance in HIV: GAPDH as a restriction factor to suppress the packaging of the primer tRNA for reverse transcription
克服 HIV 多药耐药性的策略:GAPDH 作为限制因子抑制逆转录引物 tRNA 的包装
- 批准号:
16K18922 - 财政年份:2016
- 资助金额:
$ 5.12万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
C16-Ceramide Nano-Liposomes Reverse Multi-Drug Resistance
C16-神经酰胺纳米脂质体逆转多药耐药性
- 批准号:
9921301 - 财政年份:2016
- 资助金额:
$ 5.12万 - 项目类别:
Understanding the ABCs of multi drug resistance - tying the knot on the antibacterial peptide ABC transporter McjD
了解多重耐药性的ABC - 抗菌肽ABC转运蛋白McjD喜结连理
- 批准号:
MR/N020103/1 - 财政年份:2016
- 资助金额:
$ 5.12万 - 项目类别:
Research Grant